Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis
- PMID: 35872326
- DOI: 10.1016/j.jhep.2022.07.014
Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis
Abstract
Background & aims: Hyperammonaemia is central in the pathogenesis of hepatic encephalopathy. It also has pleiotropic deleterious effects on several organ systems, such as immune function, sarcopenia, energy metabolism and portal hypertension. This study was performed to test the hypothesis that severity of hyperammonaemia is a risk factor for liver-related complications in clinically stable outpatients with cirrhosis.
Methods: We studied 754 clinically stable outpatients with cirrhosis from 3 independent liver units. Baseline ammonia levels were corrected to the upper limit of normal (AMM-ULN) for the reference laboratory. The primary endpoint was hospitalisation with liver-related complications (a composite endpoint of bacterial infection, variceal bleeding, overt hepatic encephalopathy, or new onset or worsening of ascites). Multivariable competing risk frailty analyses using fast unified random forests were performed to predict complications and mortality. External validation was carried out using prospective data from 130 patients with cirrhosis in an independent tertiary liver centre.
Results: Overall, 260 (35%) patients were hospitalised with liver-related complications. On multivariable analysis, AMM-ULN was an independent predictor of both liver-related complications (hazard ratio 2.13; 95% CI 1.89-2.40; p <0.001) and mortality (hazard ratio 1.45; 95% CI 1.20-1.76; p <0.001). The AUROC of AMM-ULN was 77.9% for 1-year liver-related complications, which is higher than traditional severity scores. Statistical differences in survival were found between high and low levels of AMM-ULN both for complications and mortality (p <0.001) using 1.4 as the optimal cut-off from the training set. AMM-ULN remained a key variable for the prediction of complications within the random forests model in the derivation cohort and upon external validation.
Conclusion: Ammonia is an independent predictor of hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis and performs better than traditional prognostic scores in predicting complications.
Lay summary: We conducted a prospective cohort study evaluating the association of blood ammonia levels with the risk of adverse outcomes in 754 patients with stable cirrhosis across 3 independent liver units. We found that ammonia is a key determinant that helps to predict which patients will be hospitalised, develop liver-related complications and die; this was confirmed in an independent cohort of patients.
Keywords: Ammonia; Ascites; Bacterial infection; Cirrhosis; Hepatic encephalopathy; Liver-related complications; Variceal bleeding.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflicts of interest Rajiv Jalan is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit Discovery, a spin out company from University College London, Hepyx Limited and Cyberliver. He had research collaborations with Yaqrit Discovery. The other authors have no conflicts of interest to declare. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Ammonia - an old friend with a new area of application.J Hepatol. 2023 Jan;78(1):e22-e23. doi: 10.1016/j.jhep.2022.08.007. Epub 2022 Aug 19. J Hepatol. 2023. PMID: 35988683 No abstract available.
-
Ammonia and prognosis of cirrhosis: A new perspective for identifying high-risk patients.J Hepatol. 2023 Feb;78(2):e69-e70. doi: 10.1016/j.jhep.2022.09.007. Epub 2022 Sep 21. J Hepatol. 2023. PMID: 36150577 No abstract available.
-
Possible link between higher ammonia levels, non-alcoholic fatty liver-related cirrhosis and diabetes: Are we missing chronic kidney disease?J Hepatol. 2023 Feb;78(2):e72. doi: 10.1016/j.jhep.2022.09.018. Epub 2022 Sep 30. J Hepatol. 2023. PMID: 36191683 No abstract available.
-
Reply to: "Ammonia - an old friend with a new area of application".J Hepatol. 2023 Jan;78(1):e23-e26. doi: 10.1016/j.jhep.2022.09.023. Epub 2022 Oct 7. J Hepatol. 2023. PMID: 36216137 No abstract available.
-
Reply to: "Possible link between higher ammonia levels, non-alcoholic fatty liver-related cirrhosis and diabetes: Are we missing chronic kidney disease?".J Hepatol. 2023 Feb;78(2):e73-e74. doi: 10.1016/j.jhep.2022.10.024. Epub 2022 Nov 1. J Hepatol. 2023. PMID: 36332694 No abstract available.
-
Reply to: "Ammonia and prognosis of cirrhosis: A new perspective for identifying high risk patients".J Hepatol. 2023 Feb;78(2):e70-e71. doi: 10.1016/j.jhep.2022.10.025. Epub 2022 Nov 2. J Hepatol. 2023. PMID: 36334687 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources